Ambrosia Biosciences, a Boulder, CO-based drug discovery company, has raised $100 million in a Series B funding round led by Blue Owl Healthcare Opportunities, Redmile, and Deep Track Capital.
The round also saw participation from BVF Partners and Boulder Ventures, and new investors Janus Henderson Investors, Samsara BioCapital, and an undisclosed institutional investor. In connection with the financing, Sara Clarke will join Ambrosia’s Board of Directors.
The company plans to use the funds to advance its novel oral small molecule GLP-1 into a Phase 1 clinical trial and to continue developing its other small molecule programs, including GIP and amylin.
Ambrosia develops orally available small molecules that target important metabolic receptors like GLP-1, GIP, and amylin. Using structural biology and advanced computational chemistry, the company designs molecules with unique effects to create both standalone treatments and combination therapies for obesity and related cardiometabolic diseases.
Read More:Kestra Raises $25M in Series A Funding
“This funding shows strong support for our team, science, and pipeline, and highlights investor confidence in next-generation oral cardiometabolic therapies,” said Nick Traggis, Founder and CEO of Ambrosia. “As the field moves beyond first-generation molecules, we see a real opportunity for unique small molecule modulators designed to work in combination. We are grateful to our new and existing investors and look forward to moving our lead programs into clinical trials.”
“With first-generation oral GLP-1 therapies now approved, we believe Ambrosia is well-positioned to create differentiated small-molecule therapies with best-in-class potential,” said Sara Clarke, Ph.D., Vice President at Blue Owl Capital. “We are excited to lead this strong group of investors and support the Ambrosia team as they move their lead GLP-1 program and broader small molecule pipeline into clinical trials.”
About Ambrosia Biosciences Inc.
Founded in 2024 by Nick Traggis, Ambrosia Biosciences Inc. is a privately held drug discovery company focused on developing orally delivered, small-molecule therapies for obesity and other metabolic disorders. The scientific team brings deep expertise across all stages of structure-based drug discovery, contributing to 30 IND filings, 25 new molecular entities, and 7 FDA approvals. With fully integrated U.S. based biology and chemistry labs, a dedicated NMR facility, and advanced structural biology and computational chemistry capabilities, Ambrosia can rapidly advance programs from initial hit to IND with exceptional speed and capital efficiency.
Read More:Censys Raises $70M in Strategic Funding
